Table 2.
HIV drug resistance mutation profiles in ART-treated individuals by subtypes.
| Mutation Proportion and (No.) (%) |
B n = 77 | CRF01_AE n = 40 | CRF07_BC n = 15 | CRF08_BC n = 16 | Others n = 10 | Total n = 158 | X2 | P |
|---|---|---|---|---|---|---|---|---|
| Resistance to nucleoside reverse transcriptase inhibitors (NRTIs) | ||||||||
| M41L | 16.9 (13) | 10.0 (4) | 6.7 (1) | 10.0 (1) | 12 (19) | 3.769 | 0.408 | |
| K65R | 1.3 (1) | 7.5 (3) | 20.0 (3) | 10.0 (1) | 5.1 (8) | 9.538 | 0.019 | |
| D67G/N/E/H/T | 10.4 (8) | 15.0 (6) | 13.3 (2) | 6.3 (1) | 20.0 (2) | 12 (19) | 1.998 | 0.75 |
| K70R/E | 11.7 (9) | 15.0 (6) | 13.3 (2) | 6.3 (1) | 10.0 (1) | 12 (19) | 0.932 | 0.947 |
| L74I/V | 2.6 (2) | 2.5 (1) | 20.0 (3) | 3.8 (6) | 6.953 | 0.073 | ||
| V75M/T/A/S/I | 1.3 (1) | 5.0 (2) | 1.9 (3) | 2.575 | 0.705 | |||
| F77L | 2.6 (2) | 7.5 (3) | 3.2 (5) | 2.4 | 0.608 | |||
| F116Y | 7.8 (6) | 5.0 (2) | 5.1 (8) | 1.581 | 0.81 | |||
| G151M | 7.8 (6) | 5.0 (2) | 5.1 (8) | 1.581 | 0.81 | |||
| M184V/I | 19.5 (15) | 67.5 (27) | 73.3 (11) | 43.8 (7) | 60.0 (6) | 41.8 (66) | 34.954 | 0 |
| L210W | 16.7 (13) | 5.0 (2) | 9.5 (15) | 7.412 | 0.074 | |||
| T215F/I/Y/S | 31.2 (24) | 12.5 (5) | 6.7 (1) | 12.5 (2) | 10.0 (1) | 20.9 (33) | 8.635 | 0.059 |
| K219E/Q/N/R | 7.8 (6) | 7.5 (3) | 13.3 (2) | 12.5 (2) | 10.0 (1) | 8.9 (14) | 1.692 | 0.82 |
| Resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) | ||||||||
| L100I | 20.0 (3) | 1.9 (3) | 6.185 | 0.127 | ||||
| K101E/Q/H/P | 9.1 (7) | 17.5 (7) | 12.5 (2) | 10 (16) | 4.312 | 0.31 | ||
| K103N/S | 40.3 (31) | 32.5 (13) | 60.0 (9) | 37.5 (6) | 50.0 (5) | 41 (64) | 3.876 | 0.427 |
| V106A/M | 9.1 (7) | 17.5 (7) | 26.7 (4) | 6.3 (1) | 20.0 (2) | 13.3 (21) | 5.346 | 0.216 |
| V179F/D/E | ||||||||
| Y181C/V/I/F | 27.3 (21) | 25.0 (10) | 6.3 (1) | 30.0 (3) | 22.2 (35) | 8.986 | 0.051 | |
| Y188C/L/H | 3.9 (3) | 5.0 (2) | 6.7 (1) | 6.3 (1) | 10.0 (1) | 5.1 (8) | 2.182 | 0.669 |
| G190A/S/E | 19.5 (15) | 32.5 (13) | 6.7 (1) | 50 (8) | 30.0 (3) | 25.3 (40) | 10.169 | 0.031 |
| P225H | 2.6 (2) | 5.0 (2) | 13.3 (2) | 6.3 (1) | 10.0 (1) | 5.1 (8) | 4.728 | 0.235 |
| M230L | 10.0 (4) | 2.5 (4) | 7.925 | 0.037 | ||||
| Resistance to protease inhibitors (PIs) | ||||||||
| L23I | ||||||||
| D30N | 1.3 (1) | 0.6 (1) | 3.609 | 1 | ||||
| M46I/L | 1.3 (1) | 2.5 (1) | 1.3 (2) | 2.21 | 1 | |||
| I50V/L | ||||||||
| F53L/Y | ||||||||
| I54V/I | 2.6 (2) | 6.3 (1) | 1.9 (3) | 3.074 | 0.536 | |||
| G73S | ||||||||
| L76V | 10.0 (1) | 0.6 (1) | 7.691 | 0.063 | ||||
| V82A/F | ||||||||
| N83D | 1.3 (1) | 6.3 (1) | 1.3 (2) | 4.043 | 0.516 | |||
| I84V | ||||||||
| I85V | 2.5 (1) | 0.6 (1) | 4.918 | 0.513 | ||||
| N88D/S | 1.3 (1) | 0.6 (1) | 3.609 | 1 | ||||
| L90M | 1.3 (1) | 0.6 (1) | 3.609 | 1 | ||||